Gbola Amusa

Catalyst Biosciences Inc (NASDAQ: CBIO), a nano-cap clinical-stage biopharmaceutical company that focuses on the treatment of hemophilia, has high expectations for its therapy for the treatment of hemophilia B. The Analyst Chardan's Gbola Amusa maintains a Buy rating on Catalyst Biosciences...

Axovant Sciences Ltd (NASDAQ: AXON)'s announcement this week that its lead drug candidate intepirdine failed in a late-stage trial comes after the stock lost 90 percent of its value over the past three months following a negative announcement on an Alzheimer's trial.  The Analyst...

Following its meeting with the FDA and the EMA, Uniqure NV (NASDAQ: QURE) announced it would expeditiously advance its adeno-associated virus, or AAV-based gene therapy, AMT-061 into pivotal trials in severe and moderately severe hemophilia B. Reacting to the announcement, Chardan maintains its...

Shares of Axovant Sciences Ltd (NASDAQ: AXON) plummeted more than 70 percent after the company's late-stage trial involving its therapy for the treatment of Alzheimer's failed to meet its primary objectives in a phase 3 study called MINDSET. Investors thinking Axovant's stock can't see any...

Shares of SAGE Therapeutics Inc (NASDAQ: SAGE) plunged Tuesday after the biopharma company announced its treatment for super-refractory status epilepticus failed its phase III trial. Chardan analyst Gbola Amusa rated the stock a Hold and said a price target was under review. Shares Fall Off A Cliff...

The Medicines Company (NASDAQ: MDCO) announced FDA approval for Vabomere injection to treat adult patients with complicated urinary tract infections. The company said the drug will be made available in the fourth quarter of 2017. Following the announcement, Chardan analyst Gbola Amusa said the...

Shares of La Jolla Pharmaceutical Company (NASDAQ: LJPC) were trading lower by more than 8 percent Monday morning after the company released Phase 3 results in the New England Journal of Medicine from a study called ATHOS-3, which evaluated the company's therapy LJPC-501 for the treatment of...

Following Ionis Pharmaceuticals Inc (NASDAQ: IONS)'s announcing positive results in a late-stage study of its anti-sense oligonucleotide, inotersen, dubbed IONIS-TTRRx, in patients with transthyretin familial amyloid polyneuropathy, or TTR-FAP, Chardan explained how the results support a pair...

Biogen Inc (NASDAQ: BIIB) and Ionis Pharmaceuticals Inc (NASDAQ: IONS) had announced on December 23, 2016, the U.S. FDA approval for Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA) types 1 to 3. Safety Concerns However, with regard to the safety profile of the drug, Chardan...

Chardan Capital names La Jolla Pharmaceutical Company (NASDAQ: LJPC) as its Top Pick for 2017,saying the company has shown one of the more compelling and convincing rare disease strategies in biotech. “By focusing on naturally-occurring peptides with well-established biological functions,...

After the close on Monday, Amgen, Inc. (NASDAQ: AMGN) announced that the U.S. District Court of Delaware had denied the motion by Sanofi SA (ADR) (NYSE: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) to stay the injunction pending the appeal of the ongoing PCSK9 litigation in the Court of...

After market close on January 5, it was announced that U.S. Federal District Court Judge Sue Robinson had ruled to issue a permanent injunction against Praluent, the PCSK9 mAb for hypercholesterolemia from partners Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (ADR) (NYSE: SNY) due to...

Following the impressive phase II ORION-1 results for the RNAi drug, inclisiran (a PCSK9 inhibitor for hypercholesterolemia), inclisiran's “expeditious” movement into phase III trials, the injunction granted against Praluent (another PCSK9 inhibitor) Thursday and with PCSK9...

Biogen Inc (NASDAQ: BIIB) shares were seen up 2.9 percent and Ionis Pharmaceuticals Inc (NASDAQ: IONS) up 4.42 percent on Tuesday following news that the FDA has approved Spinraza for treatment of spinal muscular atrophy. At the same time, shares of rival drug maker AveXis Inc (NASDAQ: AVXS) were...